Zamicastat is under clinical development by Bial – Portela & Ca and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData, Phase II drugs for Pulmonary Arterial Hypertension have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zamicastat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zamicastat overview

Zamicastat is under development for the treatment of pulmonary arterial hypertension. The drug candidate is administered through the oral route as a tablet. It acts by targeting peripheral dopamine-beta-hydroxylase (DbH). It was also under development for chronic heart failure.

Bial – Portela & Ca overview

BIAL – Portela & Ca (BIAL) is a pharmaceutical company that discovers, develops and provides drugs for neurosciences and cardiovascular therapeutic areas. It’s pipeline product portfolio includes BIA 2-093 for epilepsy, BIA 5-1058 for pulmonary arterial hypertension, BIA 9-1067 and BIA 28-6156 for Parkinson’s disease, BIA 12 for ophthalmology, BIA 19 for central nervous system, BIA 21 for cardiovascular, BIA 23, BIA 24, BIA 25, BIA 26 and BIA 27 for central nervous system. In addition, BIAL’s other products includes acariBIAL, barnix, copalia, doclis, elebrato and ferbisol, among others. The company’s products find its application in various therapeutic areas such as antibiotic therapy, cardiovascular diseases, central nervous system, immunotherapy, musculoskeletal system, and respiratory disease. BIAL provides services including research, development and scientific research. The company has its presence in Angola, Germany, Italy, Mozambique, Panama, China, the US, South Korea, Japan, Spain, Switzerland, and the UK, among others. BIAL is headquartered in Porto, Portugal.

For a complete picture of Zamicastat’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.